Dr. Zain Discusses Ongoing Trials in T-Cell Lymphomas

Jasmine Zain, MD
Published Online: Thursday, December 19, 2013
Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.

At the Center for the Lymphoid Malignancies, researchers are currently working on combining epigenetic therapies for the treatment of T-cell lymphomas. The two agents approved in this space, vorinostat and romidepsin, both have response rates close to 30%. Zain says the goal is to improve on these response rates in the relapsed setting and even move them to the upfront setting.

Activity remains to be seen in a phase I trial looking at romidepsin and 5-azacytidine. In another trial, activity is just being observed with pralatrexate and romidepsin. Both trials are open and enrolling.

Online CME Activities
Free CME from PER
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
OncoLogue: Breast Cancer Cases
More Reading
Publications
$auto_registration$